DEFA14A: Enhabit Urges Stockholders to Vote for Its Nominees Amidst Proxy Contest with AREX Capital

Enhabit files definitive proxy materials and urges stockholders to vote for its nine nominees on the YELLOW proxy card, highlighting decisive actions to stabilize the business and position the company for value creation.

Summary

• Enhabit has filed definitive proxy materials for its 2024 annual meeting, scheduled for July 25, 2024.
• The company is engaged in a proxy contest with AREX Capital Management, who is seeking to replace the majority of the Board.
• Enhabit's Board believes AREX's nominees lack sufficient experience and that their proposed Transformation Committee would destabilize the business.
• The company highlights its progress in stabilizing the business, including improving Medicare admissions, enhancing Medicare Advantage rates, growing its payor network, and increasing hospice admissions and census.
• Enhabit emphasizes its focus on driving growth through home health and hospice initiatives, de novo locations, and an employee-first culture.
• The Board defends its qualifications and experience, contrasting it with the perceived shortcomings of AREX's nominees.
• Enhabit's Board oversaw a strategic review process that included a potential sale of the company, but no formal offers were submitted due to various factors.
• The company urges stockholders to vote FOR Enhabit's nine nominees on the YELLOW proxy card.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While acknowledging past challenges and underperformance, it emphasizes the company's progress in stabilizing the business and its future growth prospects. The strong defense of the current board and criticism of the opposing slate contribute to a moderately positive outlook.

Positives

• Enhabit has stabilized Medicare admissions and is improving Medicare Advantage rates.
• The company is growing its payor network and increasing hospice admissions and census.
• Enhabit has bolstered its talent pool and is delivering consistently excellent care to patients.
• The company is making investments through its de novo strategy.
• Enhabit has an employee-first culture and has received industry and national workforce awards.
• The Board oversaw a robust strategic review process, demonstrating openness to maximizing stockholder value.

Negatives

• Enhabit's financial results and stock performance have not satisfied expectations since becoming a public company.
• The company faced challenges due to high debt levels at the time of the spin-off.
• A rapid acceleration of Medicare beneficiaries moving from Medicare to Medicare Advantage affected the company more than its peers.
• The high interest rate environment limited Enhabit's ability to be acquisitive and increased its cost of debt.
• Inflationary wage trends and labor market shortages created capacity constraints, limiting growth and increasing Enhabit's cost per visit.

Risks

• The proxy contest with AREX Capital Management could destabilize the business.
• The company's ability to execute on its strategic plans is subject to various risks and uncertainties.
• Regulatory and other developments impacting the markets for Enhabit's services could affect its performance.
• Changes in reimbursement rates, general economic conditions, and the episodic versus non-episodic mix of payers could impact results.
• The company faces risks related to attracting and retaining key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems could harm the business.
• The outcome of litigation could have a material impact.
• The company's ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures is uncertain.
• Enhabit's ability to control costs, particularly labor and employee benefit costs, is a key risk factor.

Future Outlook

Enhabit is focused on improving execution, driving growth through home health and hospice initiatives, expanding de novo locations, and leveraging its employee-first culture to enhance value for all stockholders.

Management Comments

• The Board and management team have taken the necessary steps to evolve Enhabit into a stronger, more resilient post-spin public company, well-positioned for growth.
• The only thing that matters now is setting the Company on a path that will unlock Enhabit's substantial value for all stockholders.
• The skills-based composition of a corporate board is critically important to proper board functiona wide range of talents that are tailored to the business of the corporation is vital to effective management monitoring.

Industry Context

The document highlights industry headwinds such as the shift of Medicare beneficiaries to Medicare Advantage and inflationary wage trends, which are impacting home health and hospice providers. Enhabit is positioning itself to navigate these challenges through payor innovation and cost management strategies.

Comparison to Industry Standards

• Enhabit's traditional Medicare mix of home health revenue is at approximately 60%, which is now in line with peers.
• Enhabit's 30-day hospital readmission rate was 20.5% lower than the 2022 national average, indicating superior patient care.
• Enhabit's Quality of Patient Care star rating was 16.7% better than the national average, showcasing a commitment to high-quality service.
• Enhabit is 52.3% better than the national average in hospice visits by a RN or medical social worker in two of the last three days of the patient's life, demonstrating a focus on end-of-life care.

Stakeholder Impact

• Stockholders are urged to vote to protect the value of their investment.
• Employees are supported through an employee-first culture and efforts to improve recruitment and retention.
• Patients benefit from consistently excellent care and industry-leading outcomes.
• Payors are engaged through payor innovation contracts and a growing payor network.

Next Steps

• Stockholders are urged to vote on the YELLOW proxy card for Enhabit's nine nominees.
• The Board will continue to evaluate opportunities to maximize stockholder value.
• The company will continue to execute its strategic plans, including home health and hospice initiatives, de novo locations, and payor innovation.

Key Dates

Keywords

Enhabit, proxy contest, AREX Capital Management, home health, hospice, Board of Directors, stockholders, Medicare, Medicare Advantage, payor innovation, de novo, strategic review